Effect of lemborexant on insomnia severity, morning alertness, and cognition in participants with insomnia disorder and mild obstructive sleep apnea.
Raymond Gottschalk, Alan Lowe, Jocelyn Y Cheng, Dinesh Kumar, Barbara Ramos, Margaret Moline
Sleep Med X 11 100188
摘要
摘要
OBJECTIVE: To examine the effect of lemborexant (LEM) on insomnia severity, morning alertness, and cognition in participants with COMISA (comorbid insomnia and obstructive sleep apnea [OSA]). METHODS: This post hoc analysis of study E2006-G000-304 (NCT02783729), a phase 3, randomized, double-blind, 1-month, parallel-group study of LEM 5 mg (LEM5), LEM 10 mg (LEM10), zolpidem tartrate extended-release 6.25 mg (ZOL), and placebo (PBO) included participants with insomnia and mild OSA (≥5 to <15 events/h sleep). Disease severity (assessed via Insomnia Severity Index [ISI]), cognition, and morning alertness were examined. RESULTS: This analysis included 410 participants (LEM5, n = 114; LEM10, n = 105; ZOL, n = 113; PBO, n = 78) with COMISA. Mean (SD) changes from baseline in ISI total scores were lower (improved) with LEM5 (-7.1 [5.3]), LEM10 (-7.7 [5.6]), and ZOL (-8.7 [6.7]) versus PBO (-5.7 [5.9]) at Day 31, with LEM10 and ZOL reaching statistical significance (LEM5 vs PBO: P = 0.1100; LEM10 vs PBO: P = 0.0278; ZOL vs PBO: P = 0.0011). LEM did not significantly impact next-morning cognitive functioning and alertness. ZOL negatively impacted power of attention and quality of memory cognitive domains at Days 2/3 and speed of memory retrieval at Days 30/31 versus PBO. CONCLUSION: LEM reduced insomnia severity without significantly impacting next-morning cognitive functioning and alertness in patients with mild untreated OSA.
KM 提取结果
0 个 Figure · 0 个 KM 面板